Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | ULK1 | O75385 | 3/20 | 0.44 |
| ▸ | TTK | P33981 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23441900 | 0.92 | EGFR (0.59) | EGFRBTKULK1TTKLRRK2 | |
| SCHEMBL23441669 | 0.90 | EGFR (0.58) | EGFRBTKULK1JAK2 | |
| SCHEMBL23441991 | 0.84 | EGFR (0.71) | EGFRBTKLRRK2JAK2DCLK1 | |
| Hydrochloric Acid SCHEMBL29094608 | 0.84 | EGFR (0.50) | EGFRBTKTTKLRRK2DCLK1 | |
| SCHEMBL23441888 | 0.83 | EGFR (0.61) | EGFRBTK | |
| SCHEMBL22951336 | 0.82 | EGFR (0.50) | EGFRBTKULK1LRRK2JAK2 | |
| SCHEMBL23420454 | 0.82 | EGFR (0.67) | EGFRBTKULK1 | |
| SCHEMBL23442003 | 0.82 | EGFR (0.61) | EGFRBTKALK | |
| SCHEMBL25001622 | 0.82 | EGFR (0.48) | EGFRBTK | |
| Trifluoroacetic Acid SCHEMBL29094594 | 0.81 | EGFR (0.47) | EGFRBTKULK1CDK19ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021104441-A1 | POLYAROMATIC COMPOUND AS EGFR KINASE INHIBITOR | 江苏先声药业有限公司 | 2021-06-03 | — | — | WO | disclosed |